Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain–Barré syndrome: a possible prognostic biomarker for disability at 12 months | Synapse
April 10, 2026Open Access
Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain–Barré syndrome: a possible prognostic biomarker for disability at 12 months
Key Points
The study aims to evaluate the potential of cerebrospinal fluid alpha-internexin concentrations as a prognostic biomarker for disability in Guillain-Barré syndrome.
Measured cerebrospinal fluid alpha-internexin concentrations at diagnosis.
Evaluated long-term outcomes after 12 months.
Assessed the relationship between CSF AINX levels and patient recovery.
Elevated CSF alpha-internexin concentrations at diagnosis correlated with poorer long-term outcomes.
High levels suggest potential CNS-related injury influencing recovery.
Abstract
Elevated CSF AINX at diagnosis was associated with poor long-term outcome in GBS, consistent with a possible contribution of CNS-related injury to recovery.